Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Flail Chest-II01:26

Flail Chest-II

184
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
184
Pneumothorax-II01:27

Pneumothorax-II

170
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
170
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

Clinical lung cancer·2026
Same author

Post-Pneumonectomy Syndrome Causing Reversible Right Ventricular Dilation and Tricuspid Regurgitation.

JACC. Case reports·2026
Same author

Cellular Therapies in Solid Tumors: Are We Ready for Primetime?

JCO oncology practice·2026
Same author

Immune Checkpoint Inhibitors in Unresectable or Metastatic Thymic Epithelial Tumors--A Real-World Assessment of Efficacy and Toxicity.

Clinical lung cancer·2026
Same author

Extracorporeal Membrane Oxygenation for Pneumocystis Pneumonia: Outcomes in Patients From the Extracorporeal Life Support Organization.

Critical care explorations·2026
Same author

From Diagnosis, Therapy Decision-Making to Genetic Risk Assessment: The Impact of ctDNA Testing on Comprehensive Cancer Management-A Case Report.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Related Experiment Video

Updated: Jul 12, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Hyperthermic intrapleural chemotherapy: an update.

Megan E Campany1, Pedro A Reck Dos Santos2, Britton B Donato3

  • 1Mayo Clinic Alix School of Medicine, Scottsdale, AZ, USA.

Journal of Thoracic Disease
|October 23, 2023
PubMed
Summary
This summary is machine-generated.

Hyperthermic intrathoracic chemotherapy (HITHOC) shows promise for pleural malignancies but lacks standardized guidelines. Further research and a pleural cancer index could improve its application alongside cytoreductive surgery.

Keywords:
Intrapleural chemotherapycytoreductive surgery (CRS)hyperthermic chemotherapypleural malignancy

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.0K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K

Related Experiment Videos

Last Updated: Jul 12, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.0K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Surgical Oncology

Background:

  • Hyperthermic intrathoracic chemotherapy (HITHOC) is an adjunct to cytoreductive surgery (CRS) for pleural malignancies like mesothelioma.
  • HITHOC enhances cytotoxic agent penetration in the hyperthermic environment, crucial for challenging microscopic resections in pleural cancers.
  • Current literature shows varied HITHOC techniques and outcomes, despite a favorable risk profile.

Purpose of the Study:

  • To address the ambiguity in National Comprehensive Cancer Network (NCCN) guidelines regarding the benefit of HITHOC.
  • To highlight the need for standardization in HITHOC utilization for pleural malignancies.
  • To propose initiatives for wider application of HITHOC in managing pleural cancers.

Main Methods:

  • Review of current literature on HITHOC in pleural malignancies.
  • Analysis of NCCN guidelines and their limitations concerning intraoperative adjuvant therapies.
  • Proposal for a task force and a pleural cancer index to standardize HITHOC.

Main Results:

  • HITHOC's safety and efficacy are demonstrated, particularly for mesothelioma and other pleural metastases.
  • A lack of definitive recommendations and standardization hinders HITHOC's broader use.
  • The low prevalence of eligible patients contributes to the limited evidence base.

Conclusions:

  • Standardization of HITHOC techniques is needed to improve outcomes for patients with pleural malignancies.
  • A dedicated task force and a pleural cancer index could facilitate wider adoption and consistent application of HITHOC.
  • Further investigation is warranted to solidify HITHOC's role in the surgical management of pleural cancers.